首页> 美国卫生研究院文献>Clinical Ophthalmology (Auckland N.Z.) >Intravitreal triamcinolone acetonide for rebound phenomenon after high-dose intravenous steroid treatment in Vogt-Koyanagi-Harada disease
【2h】

Intravitreal triamcinolone acetonide for rebound phenomenon after high-dose intravenous steroid treatment in Vogt-Koyanagi-Harada disease

机译:玻璃体内曲安奈德治疗大剂量静脉类固醇治疗Vogt-Koyanagi-Harada病后的反弹现象

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The authors report two cases of rebound phenomenon treated with intravitreal triamcinolone acetonide in Vogt-Koyanagi-Harada (VKH) disease. Patients in the acute phase of VKH disease were treated with high-dose intravenous (IV) methylprednisolone (1 g/day) for 3 days. Serous retinal detachment decreased and visual acuity improved during IV steroid treatment. After switching to oral steroid treatment, choroiditis and visual acuity worsened. An injection of triamcinolone acetonide (4 mg) into the vitreous resulted in gradual resolution of subretinal fluid and improvement of visual acuity. Systemic steroids were tapered to discontinuation without a relapse of inflammation. Adjuvant intravitreal triamcinolone is useful in the management of the rebound phenomenon in VKH disease.
机译:作者报告了2例玻璃体腔注射曲安奈德治疗Vogt-Koyanagi-Harada(VKH)疾病的反弹现象。 VKH疾病急性期的患者接受大剂量静脉内(IV)甲基泼尼松龙(1 g /天)治疗3天。静脉类固醇治疗期间浆液性视网膜脱离减少,视力提高。改用口服类固醇激素治疗后,脉络膜炎和视力恶化。向玻璃体内注射曲安奈德(4毫克)可逐渐消除视网膜下液并改善视力。全身性类固醇逐渐减少至停药,没有炎症复发。佐剂玻璃体内曲安奈德可用于控制VKH疾病的反弹现象。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号